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Truncating variants in the TTN gene (TTNtv) are the commonest cause of heritable DCM. This 
study aimed to study the phenotypes and outcomes of TTNtv carriers. 
 
Methods:  
537 individuals (61% male; 317 probands) with TTNtv were recruited in 14 centers [372 (69%) 
with baseline left ventricular systolic dysfunction (LVSD)]. Baseline and longitudinal clinical 
data were obtained. The primary-endpoint was a composite of malignant ventricular arrhythmia 
(MVA) and end-stage heart failure (ESHF). The secondary endpoint was LV reverse 
remodelling (LVRR) [LVEF increase by ≥10% or normalization to ≥50%].  
 
Results:  
Median follow-up was 49 [18-105] months. Males developed LVSD more frequently and 
earlier than females (45±14 vs 49±16 years respectively; p=0.04). By final evaluation, 31%, 
45% and 56%  had AF, frequent ventricular ectopy and NSVT respectively.  
 
76 (14.2%) individuals reached the primary-endpoint [52 (68%) ESHF-events, 24 (32%) 
MVA-events]. MVA-endpoints most commonly occurred in patients with severe LVSD. 
Male sex (HR 1.89, 95%CI: 1.04-3.44; p=0.04) and LVEF [per 10% decrement from LVEF 
50%] (HR 1.63, 95%CI: 1.30-2.04; p<0.001) were independent predictors of the primary-
endpoint.  
 
207/300 (69%) patients with LVSD had evidence of LVRR. In a subgroup of 29/74 (39%) 
patients with initial LVRR, there was a subsequent LVEF decrement.  
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TTNtv location was not associated with statistically-significant differences in baseline 
clinical characteristics, LVRR or outcomes on multivariable analysis (p=0.07).  
 
Conclusions:  
TTNtv is characterized by frequent arrhythmia but MVA are most commonly associated with 
severe LVSD. Male sex and LVSD are independent predictors of outcomes. Mutation 
location does not impact clinical phenotype or outcomes.  
 
Keywords: Titin, Dilated Cardiomyopathy, Sex, LV reverse remodelling, Heart Failure. 
 
Clinical implications 
The good response to optimal medical therapy emphasises the need to identify and treat 
patients with TTNtv as soon as left ventricular systolic dysfunction appears. Patients should 
remain under close surveillance to detect atrial and ventricular arrhythmia and left ventricular 
systolic dysfunction recurrence following initial let ventricular reverse remodelling. 
Malignant ventricular arrhythmia predominantly occurs in patients with severe left 
ventricular systolic dysfunction and supports recommendations for prophylactic implantable 
cardioverter-defibrillators in patients with advanced disease. Patients with TTNtv have a 
similar clinical phenotype and outcome irrespective of TTNtv location with respect to the A-
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SCD  Sudden Cardiac Death 
TTE  Transthoracic Echocardiogram 
TTN  Titin gene 
TTNtv  Truncating variants in the TTN gene 
VAD  Ventricular Assist Device 
VE  Ventricular Ectopy 
VF  Ventricular Fibrillation 







Phenotypes and Prognosis of Dilated Cardiomyopathy (DCM) Caused by 
Truncating Variants in the Titin (TTN) gene 
 
INTRODUCTION 
Dilated cardiomyopathy (DCM) has an estimated population prevalence of 1:250 and is the 
commonest cause for heart transplantation (HTx) worldwide.1, 2 More than 25% of patients 
with DCM have a genetic predisposition 2, 3 and emerging data suggest that genotype has an 
important impact on prognosis and therapy.4-6  
 
Truncating variants in the TTN gene (TTNtv), encoding the giant protein titin, are the 
commonest genetic subtype of DCM, accounting for up to 25% of cases.7, 8  Titin is an 
integral sarcomeric protein involved in passive force transmission and plays essential roles in, 
sarcomere organization, elasticity and cell signalling.9 In some studies, TTNtv associated 
with DCM appear to be highly enriched in the A-band 7 but more recently, TTNtv mutations 
in other constitutively-expressed exonic regions have also been implicated in DCM.10, 11 In 
addition, previous studies on TTNtv are inconsistent with respect to arrhythmia burden 10, 12-
16, response to optimal medical therapy (OMT) 12, 13, 17, 18, impact of mutation location 7, 10, 11, 
19, 20 and prognosis.7, 10, 13, 14 In this study, we report the characteristics and outcomes of a 
large international cohort of consecutive probands and relatives with TTNtv. 
 
METHODS 
This study conforms to the principles of the Helsinki declaration and all authors guarantee the 
integrity of data from their respective institutions. Approval from a local ethics committee / 
internal review board was obtained at each participating center. The data that support the 
findings of this study are available from the corresponding author upon reasonable request. 
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Cohort composition  
This is a multi-center, longitudinal cohort study comprising consecutive probands and 
relatives evaluated in 13 European and 1 Australian cardiomyopathy unit between 1985 and 
2019.  Inclusion criteria for probands were patients with idiopathic left ventricular systolic 
dysfunction (LVSD) unexplained by abnormal loading conditions or coronary artery disease; 
or the presence of a familial history of cardiomyopathy with an abnormal cardiac phenotype 
(left ventricular dilatation, atrial or ventricular arrhythmia, abnormal T-wave inversion on 
ECG) (Supplementary Methods S1). Only probands with a pathogenic or likely pathogenic 
TTNtv were included. Relatives were included if they carried a pathogenic or likely 




Genetic testing in probands was undertaken using targeted next generation, whole exome or 
whole genome sequencing at participating institutions or at an accredited genetics laboratory 
with no a priori selection based on clinical phenotype or adverse events. Presence of a 
familial history of DCM was not mandatory for genetic testing and varied according to 
routine institutional practice. Sanger sequencing was used for cascade screening in relatives. 
Likely-pathogenic TTNtv were novel or rare variants located in constitutively expressed 
exons with a percentage spliced index (PSI)>90% and with a minor allele frequency (MAF) 
<0.01% in control populations using gnomAD browser [www.gnomad.broadinstitute.org] 
(Supplementary Methods S1).11, 20 Patients with additional pathogenic mutations in other 




Demographics, symptoms, 12-lead electrocardiogram (ECG), transthoracic echocardiogram 
(TTE) and, where available, ambulatory-ECG and cardiac magnetic resonance (CMR) 
imaging were collated from clinical records. Data were collected independently at each 
participating center using uniform methodology.  
 
LVSD was defined as left ventricular ejection fraction (LVEF) <50% on TTE or CMR. Mild, 
moderate and severe LVSD were defined as LVEF values of 45-49%, 36-44% and ≤35%, 
respectively. DCM, LV dilatation, non-sustained ventricular tachycardia (NSVT), frequent 
ventricular ectopy (VE≥500/24-hours) and atrial fibrillation (AF) were defined using 
consensus recommendations (Supplementary Methods S1).21  
 
Study endpoints 
The primary survival endpoint was a composite of malignant ventricular arrhythmia (MVA) 
[sudden cardiac death (SCD), aborted SCD, appropriate implantable cardioverter-defibrillator 
(ICD) shock] and end stage heart failure (ESHF) [destination ventricular assist device 
(VAD), HTx or ESHF-mortality]. Patients were censored at the time of their first endpoint 
event or at last evaluation. Only events occurring during follow-up at participating centers 
were included. 
 
The secondary-endpoint was LV reverse remodelling (LVRR) with optimal medical therapy, 
defined as either LV normalization (LVEF improvement to ≥50% with a ≥5% improvement 




Follow-up duration for each patient was calculated from baseline clinical evaluation at 
participating centers to the date of their first study endpoint, death from another cause or the 
date of last evaluation.  
 
Statistical analysis 
Analyses were performed using SPSS Statistics version 25.0 (IBM, New York). A 2-sided p-
value < 0.05 defined statistical significance. Variables are expressed as counts (percentages), 
mean ± standard deviation (SD), and median [lower quartile-upper quartile] as appropriate. 
Chi-squared analysis or Fisher’s-exact test was used to compare categorical data between 
groups. The independent samples Student t-test or ANOVA test was used to compare 
normally-distributed continuous data between groups and the Mann-Whitney U test was used 
to compare the distribution of skewed continuous data between groups.  
 
Univariable Cox regression was used to assess the association of baseline variables with the 
primary-endpoint after confirmation that the proportional hazards assumption remained valid. 
Predictors with p <0.05 on univariable analysis were incorporated into a multivariable Cox-
regression model to calculate hazard ratios (HR) and 95% confidence intervals (CI).  
 
Kaplan-Meier (KM) plots were used to display the cumulative probability of the occurrence 
of LV systolic dysfunction (penetrance) and of the occurrence of the composite primary-
endpoint for the entire cohort and when stratified according to patient sex and TTNtv 




565 patients with TTNtv were identified; 28 were excluded due to re-classification of a 
TTNtv to a ‘variant of unknown significance’ or due to co-inheritance of a pathogenic 
mutation in another DCM causing gene. The final cohort comprised 537 individuals [317 
(59%) probands; 328 (61%) males] with a median family size of 1 [1-2] individual including 
probands. 220 families contributed only a single proband to the cohort; 97 families 
incorporated multiple individuals with a median family size of 3 [2-4] individuals including 
probands.  
 
The overall cohort comprised 267 distinct TTNtv [125 nonsense, 129 frameshift and 13 
canonical splice-site variants] with a mean of 1.2 probands per TTNtv (Figure 1, 
Supplementary Tables S1 and S2). 229 TTNtv were unique to individual probands, 28 
variants were present in 2 unrelated probands, 8 variants were present in 3 unrelated probands 
and 2 variants were present in 4 unrelated probands.  
 
286 (90.2%) probands were of Caucasian ethnicity, 9 (2.8%) were Asian, 5 (1.6%) were 
Afro-caribbean and 17 (5.4%) were of mixed or other ethnicities. 246 (78%) probands had 
TTNtv located in the A-band domain and 71 (22%) had TTNtv in non-A band domains [45 
(14%) I-band, 18 (6%) M-band and 8 (2%) in the Z-disk region]. 
 
The baseline characteristics of the cohort are summarized in Table 1. 185 (58.4%) probands 
had a FH of DCM and 87 (27.4%) a FH of SCD. The commonest presenting symptom in the 
entire cohort was NYHA class ≥3 dyspnoea in 148 (28%) followed by palpitations in 109 
(21%). Syncope occurred in 15 (3%) at baseline.   
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53 (10%) patients had AF identified on baseline ECG. The median LVEF was 30% [20-40%] 
in probands and 56% [45-60%] in relatives (p<0.001). Probands had a more advanced 
phenotype than relatives (Supplementary Table S3); 77/220 (35%) relatives had LVSD at 
baseline of whom 23 (30%) were entirely asymptomatic. 
 
Ambulatory-ECG findings at baseline evaluation 
272 (51%) patients had a baseline Holter as part of routine institutional practice, irrespective 
of symptoms or clinical phenotypes. AF was present on baseline Holter in 44/272 (16%).  
 
AF was documented on baseline ECG or Holter in 86/537 (16%) individuals and preceded 
LVSD in 14/165 (8.5%) of patients with a normal LVEF. 53 (62%) of patients with AF on 
baseline ECG or Holter were asymptomatic with respect to palpitations. 
 
The prevalence of AF at baseline evaluation was 7/42 (17%), 14/70 (20%) and 48/242 (20%) 
in patients with mild, moderate and severe LVSD, respectively. Patients with AF and 
impaired LVEF were of similar age to TTNtv patients with AF and preserved LVEF at 
baseline evaluation (54±14 vs 59±17 years respectively; p=0.24). Patients with AF on 
baseline ECG or Holter had larger left atrial dimensions than those without evidence of AF 
[parasternal long axis dimension on TTE 44±9 vs 39±8mm (p<0.0001) and 4-chamber left 
atrial area on CMR 32.2±8.1 vs 26.7±8.0 cm2 (p=0.03), respectively]. 
 
74/187 (40%) patients had frequent VE (median 213 [11-1765] VE/24 hours) and 126/272 
(46%) had NSVT (median of 2 runs of NSVT/24 hours) on baseline Holter. VEs were 
polymorphic in 57% and monomorphic in 43%. VE burden correlated with the severity of 
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LVSD (p <0.001) (Figure 2A). In TTNtv patients with preserved LVEF, NSVT and frequent 
VE on baseline Holter occurred in 5/52 (10%) and 10/43 (23%), respectively.  
 
Cardiac Magnetic Resonance Imaging 
209 patients had CMR imaging data available; 100 (48%) had late gadolinium enhancement 
(LGE); the presence of any degree of LGE correlated with progressive severity of  LVSD; 
p<0.001) (Figure 2B). The presence of LGE on baseline CMR was associated with baseline 
NYHA class III-IV dyspnoea (40% vs 18%; p=0.001), AF (21% vs 8%; p=0.04), NSVT 
(60% vs 35%; p=0.01), and increased VE burden (median 337 [31-2457] vs 58 [3-789] /24 




Males were more likely to be probands (68% vs 45%; p<0.001). Male probands were also 
more likely to be in NYHA class III-IV (44% vs 33%; p=0.07) and had lower baseline LVEF 
(29±13% vs 32±11%; p=0.04). Male probands had a higher prevalence of AF on baseline 
Holter (20% vs 5%; p=0.009), NSVT (58% vs 42%; p=0.046) and LGE on baseline CMR 




332/351 (95%) patients with LVSD (at baseline or during follow-up) received ACE inhibitors 
or angiotensin receptor blockers, 324/350 (93%) ß-blockers and 238/346 (69%) 
mineralocorticoid receptor antagonists; 51/347 (15%) patients were switched to an 
angiotensin receptor-neprilysin inhibitor (ARNI), 50/348 (14%) were on ivabradine and 
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4/345 (1%) received a nitrate/hydralazine combination; 214/347 (62%) patients required oral 
loop diuretics. At last evaluation, 120 (22%) patients had an ICD for primary prevention and 
20 (4%) for secondary prevention indications; 31 (6%) patients had cardiac resynchronization 
therapy (CRT). 
 
Clinical phenotypes during follow-up 
At baseline evaluation, 372 (69%) individuals had LVSD, 49 (9%) had cardiac abnormalities 
suggestive of phenotypic expression including abnormal T-wave inversion on ECG, isolated 
LV dilatation, LGE on CMR or atrial or ventricular arrhythmia, and 116 (22%) were phenotype 
negative. During a median follow-up of 49 [18-105] months (total of 2822 patient years), 25 
(4.7%) patients with normal baseline LVEF developed LVSD. By final evaluation, 397 (74%) 
patients had evidence of LVSD and 39 (7%) had cardiac abnormalities suggestive of 
phenotypic expression (Supplementary Methods S1). Patients with low-normal LVEF 
(LVEF 50-55%) at baseline evaluation were more likely to develop LVSD during follow-up 
compared to those with LVEF ≥55% (21/41 (51%) vs 4/122 (3%); p<0.001). 
 
Male TTNtv patients developed LVSD more frequently and at a younger age than females 
(85% vs 57%; mean age at diagnosis of LVSD (at baseline or over follow up): 45±14 vs 49±16 
years, respectively; p=0.04) (Figure 3; Supplementary Figure S1-3).  
 
During follow-up, there were 74 new cases of AF identified on ECG or Holter. At final 
evaluation, AF, frequent VE, NSVT and sustained VT were identified in 160/537 (30%), 
92/204 (45%), 157/281 (56%) and 46/537 (9%) of the overall TTN cohort respectively.  
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In the 160 patients with AF at final evaluation, AF was paroxysmal in 105 (66%), persistent 
in 19 (12%) and permanent in 36 (22%). 6 of 140 (4%) patients with an ICD had an 
inappropriate ICD shock due to rapidly conducted AF. 14 patients (2.6%) had 
hemodynamically stable sustained VT treated with antitachycardia pacing (ATP) in the 
absence of a primary-endpoint event (12 patients with baseline severe LVSD and individual 
patients with baseline mild or moderate LVSD).  
 
Clinical events during follow-up 
Primary endpoint 
There were 76 (14.2%) primary-endpoint events: ESHF in 52 (68%) and MVA in 24 (32%). 
The most frequent ESHF endpoint was HTx (n=40), followed by ESHF-mortality (n=11) and 
VAD (n=1). MVA endpoints were most commonly appropriate ICD shocks for VT / VF 
(n=17), followed by aborted SCD (n=4) and SCD (n=3) (Figure 4); 16 (3%) patients had 
multiple MVA and/or ESHF endpoints. All endpoint events occurred in patients with LV 
systolic dysfunction at baseline or over follow-up (Supplementary Table S4)].  
 
Univariable baseline predictors of the primary endpoint are shown in Table 2. Baseline 
parameters with a univariable p-value of <0.05 were incorporated into a multivariable model 
including proband status as a first step, followed by forward conditional Cox regression 
multivariable modelling of other baseline variables. As only a minority of patients underwent 
baseline Holter monitoring, NSVT was excluded from the multivariable model to minimise 
case-censoring of incomplete data. Multivariable modelling included proband status as a first 
step, followed by  male sex, A-band TTNtv mutation location, LV dilatation and LVEF [per 
10% decrement from LVEF 50%]. Multivariable Cox regression incorporating 482 patients 
(71 events), demonstrated that male sex (HR 1.89, 95%CI: 1.04-3.44; p=0.04) and LVEF [per 
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10% decrement from LVEF 50%] (HR 1.63, 95%CI: 1.30-2.04; p<0.001) were independent 
predictors of the primary endpoint (Table 2, Figures 5A & 5B).  
 
There were no statistically significant associations between TTNtv variant location with 
respect to TTN-band or cronos alternative promoter location and baseline clinical 
characteristics, age at LVSD penetrance or response to optimal medical therapy 
(Supplementary Tables S5-6, Supplementary Figure S4). Patients with A-band TTNtv had 
reduced cumulative survival from the composite primary endpoint from baseline clinical 
evaluation compared to patients with non-A band TTNtv on univariable analysis (HR 2.12; 
95%CI: 1.11-4.05; p=0.02) only, but this was not statistically significant on multivariable 
modelling (HR 1.85; 95%CI: 0.96-3.56; p=0.07) from baseline evaluation or on a univariable 
proband-only analyses from birth (HR 1.16; 95%CI: 0.66-2.05; p=0.61) or baseline 
evaluation (HR 1.33; 95%CI: 0.69-2.57; p=0.39) (Figure 5C, Supplementary Figure S5). 
Similarly, when probands with TTNtv location prior to or post- cronos, the internal TTN 
promotor were assessed, there was no statistically significant difference in cumulative 
survival from the composite primary endpoint from birth (p=0.73) or baseline clinical 
evaluation (p=0.39). 
 
Secondary endpoint  
LV reverse remodelling was assessed in 300 patients with LVSD and serial echocardiograms. 
LVRR occurred in 207 (69%) patients [LVEF normalization in 117 and LVEF improvement 
≥10% in 90]. LVRR occurred in 64%, 57% and 74% in those presenting with mild, moderate 
and severe LVSD, respectively. The mean absolute LVEF improvement from baseline to 
final evaluation was 11±14%.  
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Patients with LVRR had fewer primary-endpoint events compared to those without LVRR 
(p<0.001) despite similar follow-up duration from DCM-onset (77±63 vs 78±60 months 
respectively) (Figure 5D). There were no statistically significant differences in sex [134 
(68%) vs 65 (75%) men; p=0.28], A-Band TTNtv [150 (77%) vs 65 (75%); p=0.74], baseline 
LVEF (30.0±10.9 vs 31.2±10.8%; p=0.12) or presence of LGE [49 (53%) vs 19 (56%); 
p=0.75] between those with and without LVRR respectively (Supplementary Table S7). In 
a sub-group of 74 patients with LVRR and subsequent serial TTE (post-LVRR), there was 
evidence of a reduction in LVEF by ≥10% despite OMT in 29 (39%) (Supplementary 
Methods S1).  
 
DISCUSSION 
This study demonstrates that DCM caused by penetrant TTNtv is associated with frequent 




In our cohort, more than 30% of relatives had LVSD at baseline, of whom almost one third 
were asymptomatic despite the presence of impaired LV systolic function. This shows the 
value of cascade genetic testing and clinical screening in relatives to allow the timely 
commencement of prognostic medical therapy. Similarly, the fact that 4.7% of TTNtv 
carriers without DCM at baseline, went on to develop disease over follow-up, is an 
illustration of the importance of longitudinal follow-up of presymptomatic mutation carriers. 
 
High prevalence of atrial and ventricular arrhythmia 
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Previous studies have reported contradictory data on the prevalence of atrial and ventricular 
arrhythmia in TTNtv carriers. Some have suggested that AF occurs in up to a third of patients  
with TTNtv 12-14 and that TTNtv are associated with a 3-fold increased odds of early atrial 
arrhythmia compared to non-TTN DCM.15, 22, 23 In contrast, others have suggested a similar 
incidence of AF in TTN- and non-TTN DCM.12, 15, 24 This study shows that the TTNtv 
phenotype is characterised by both atrial and ventricular arrhythmias with almost one third of 
patients developing atrial arrhythmias and one half NSVT. Importantly, nearly 10% of TTNtv 
carriers with preserved LVEF developed AF or NSVT, highlighting the need for regular 
Holter monitoring in all individuals with TTNtv.22 
 
Prognosis and response to medical therapy 
Initial studies of TTNtv suggested they are associated with fewer adverse events than 
idiopathic or other genetic forms of DCM.7, 8, 12-14, 17, 24, 25 Our  study demonstrates that TTNtv 
carriers are prone to ESHF and MVA, with a predominance of heart failure events. 
Importantly, the majority of malignant arrhythmic events in both sexes occurred in patients 
with severe LVSD supporting adherence to consensus EF <35% based thresholds for primary 
prevention ICD implantation.  
 
OMT was associated with left ventricular reverse remodelling in the majority of patients.  
The frequency of LVRR is considerably higher than values reported previously in idiopathic 
DCM cohorts 26, 27 and is associated with a better prognosis. In order to determine the 
sustainability of structural remodelling, we examined long term changes in LVEF in a subset 
of patients with serial TTE after LVRR, and observed some late deterioration in LVEF. This 
phenomenon needs to be studied in larger cohorts, but the data suggests that continued long-
term LVEF monitoring is required, even when patients respond favorably to medical therapy.  
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Impact of sex on outcomes  
This study demonstrates that males with TTNtv have earlier disease penetrance and a more 
advanced phenotype including larger indexed LV dimensions, lower LVEF, more atrial 
arrhythmia and frequent LGE on CMR. Despite similar LVRR rates on OMT when compared 
to females, males also have more adverse events and reduced survival on multivariable 
modelling compared to females. This sex-related risk is unexplained but is not unique to TTN 
having been demonstrated in other forms of dilated or arrhythmogenic cardiomyopathy.4, 16, 
28, 29  
 
Mutation location and clinical phenotype 
Some studies have shown that TTNtv mutation location has no effect on cardiac phenotype 15 
whereas others have suggested an attenuated cardiac phenotype in patients with TTNtv 
located in non-A band domains or located pre-cronos due to rescue from an internal TTN 
promoter.7, 10, 19 In this study of the largest cohort of TTNtv patients to date, we demonstrate 
no statistically significant difference in baseline clinical phenotypes or age of LVSD 
penetrance associated with TTNtv located across different TTN-bands or positions with 
respect to pre- or post-cronos alternative promoter location. There was a trend towards a 
poorer prognosis in TTNtv located in the A-band on univariable analysis compared to non-A 
band TTNtv, but this trend was statistically non-significant on multivariable modelling or on 
a proband-only survival analysis from birth or baseline clinical evaluation. 
 
What is new? 
 Male sex is associated with more advanced clinical phenotype and adverse outcomes 
compared to females. 
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 Both male sex and left ventricular ejection fraction are independent predictors of 
adverse events. 
 TTNtv mutation location in the predominantly adult splice TTN-isoforms 
[www.cardiodb.org/titin], with respect to A-band or cronos does not impact on 
clinical phenotypes or outcomes. 
 LV reverse remodelling is frequent with medical therapy, but LV systolic function 
can deteriorate in the long term.  
 
CONCLUSION 
Dilated cardiomyopathy caused by TTNtv is characterized by frequent atrial and ventricular 
arrhythmia and a high rate of LV reverse remodelling with optimal medical therapy. 
Malignant ventricular arrhythmias are predominantly associated with severe left ventricular 
systolic dysfunction. Male sex and left ventricular ejection fraction are independent 
predictors of adverse outcomes. When strict criteria for TTNtv pathogenicity or likely-
pathogenicity is taken into account [www.cardiodb.org/titin], TTNtv location (in 
predominantly adult splice TTN-isoforms) does not influence clinical phenotype or outcomes. 
  
LIMITATIONS 
The participating centers are all tertiary referral units and so the results of the study may be 
prone to referral bias and may not be generalisable in all clinical scenarios. The majority of 
this cohort are symptomatic probands and given the incomplete penetrance of TTNtv, there 
may be a selection bias towards those with a more advanced phenotype. While the findings of 
this study were unchanged when proband-only analyses were undertaken, an impact of 
relatives biasing the study cannot be excluded.  
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Although there is a high a priori probability that the TTNtv variants are pathogenic due to 
extensive genetic panel for DCM-causing genes and strict inclusion criteria for TTNtv with 
PSI >90% and MAF<0.01%, cosegregation data were limited.  
 
Given the long duration of enrolment, there is a potential for calendar year to be a confounder 
for clinical outcomes. The longitudinal nature of this real world data means that missing data 
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Table 1: Baseline demographic and clinical data of 537 TTNtv patients stratified 
according to baseline left ventricular systolic dysfunction (ms: milliseconds; PLAX: 
Parasternal Long Axis; * A minority of probands had normal LVEF at baseline – this was due 
to some having a FH of DCM / SCD and being genetically tested due to an abnormal cardiac 
phenotype with LV dilatation, atrial / ventricular arrhythmia or low-normal LVEF (EF 50-
55%) or due to a prior DCM diagnosis and subsequent improvement in LVEF (on OMT) prior 
to transfer of care to a participating institution). 
 
Table 2: Univariable and Multivariable Predictors of the primary-endpoint using 
baseline clinical data obtained from clinical evaluation, ECG, TTE, CMR and Holter. 
*NSVT was not included in multivariable Cox regression model to minimise case-censoring. 
Proband status was included into the model as a first step and forward conditional Cox-
regression using sex, LVEF (per 10% decrement from LVEF 50%), LV dilatation and TTN A-
band location. TTN A-band location (p=0.07) and LV dilatation (p=0.23) were removed from 
the equation on multivariable modelling due to a lack of statistical significance. This model 
incorporated 71 events and 482 (90%) patients. 
 
Figure 1: Picture demonstrating the location of TTNtv in this cohort with respect to TTN-
band. The green triangles represent the locations of the different TTNtv. The orange bar 
underneath represents the corresponding exon location in the TTN metatranscript. The bar 
underneath displays the corresponding TTN-band. The thin grey bars represent the PSI for the 
different exons as described in previous studies [www.cardiodb.org/titin] 10. All incorporated 
TTNtv were in exons with PSI >90% and were constitutive including in the N2B and N2BA 
isoforms of TTN.  
 
 31 
Figure 2A: Box-Plot demonstrating the VE-burden/24 hours on baseline Holter 
assessment for the overall cohort (probands and relatives) - stratified according to LVEF 
category. 
 
Figure 2B: Bar-chart demonstrating the percentage of TTNtv patients with LGE on 
CMR for the overall cohort (probands and relatives) - categorised according to LVEF on 
CMR.  
 
Figure 3: Bar-chart demonstrating age-related onset of LVSD for the overall TTNtv 
cohort and stratified according to sex and proband status. [KM curves for LVSD 
penetrance demonstrated in Supplementary Figures S1-3]. 
 
Figure 4: Flow-chart demonstrating the outcomes of patients (stratified with respect to 
LV systolic dysfunction) with TTNtv over follow-up with respect to arrhythmic- and HF-
endpoints.  
 
Figure 5A: KM-survival analysis from baseline evaluation for the composite primary-
endpoint stratified according to the presence of baseline LVSD. 71 endpoint events 
occurred in patients with baseline LVSD compared to 5 events in patients with baseline 
normal LVEF (p=0.003). 
 
Figure 5B: KM-survival analysis from baseline evaluation for the composite primary-
endpoint stratified according to male sex. 61 endpoint events occurred in male patients 
compared to 15 events in female patients (p=0.002).  
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Figure 5C: KM-survival analysis from baseline evaluation for the composite primary-
endpoint  for TTN-probands stratified according to TTN mutation location with respect 
to A-band. 50 endpoint events occurred in A-band TTNtv patients compared to 11 events in 
non A-band TTNtv patients (p=0.39).  
 
Figure 5D: KM-survival analysis from baseline DCM echocardiogram for the composite 
primary-endpoint stratified according to occurrence of LVRR on OMT. 26 endpoint 
events occurred in TTNtv patients without LVRR compared to 16 events in TTNtv patients 
with evidence of LVRR (p<0.001). 
 
 
















p-value for  
comparator 
Proband* 537 317 (59%) 295 (79%) 22 (13%) <0.001 
Male Sex 537 328 (61%) 259 (70%) 69 (42%) <0.001 
Caucasian Ethnicity 537 496 (92%) 336 (90%) 160 (97%) 0.04 
TTNtv  PATHOGENIC / LIKELY-PATHOGENIC VARIANT CHARACTERISTICS 
A-Band 537 414 (77%) 288 (77%) 126 (76%) 0.79 
Post-Cronos 537 468 (87%) 323 (87%) 145 (88%) 0.74 
BASELINE CLINICAL EVALUATION 
Mean Age (years) 536 44 ± 16  47 ± 15 38 ± 17 <0.001 
NYHA Class III-IV  523 148 (28%) 145 (40%) 3 (2%) <0.001 
Syncope  522 15 (3%) 13 (4%) 2 (1%) 0.17 
Palpitations  522 109 (21%) 88 (24%) 21 (13%) 0.003 
BASELINE ECG 
 1 
PR Interval (ms) 386 167 ± 30 174 ± 30 156 ± 26 <0.001 
QRS Duration (ms) 422 96 ± 19 101 ± 20 86 ± 11 <0.001 
Abnormal T-wave inversion  484 139 (29%) 131 (40%) 8 (5%) <0.001 
Low QRS Voltage Limb leads 485 60 (12%) 40 (12%) 20 (13%) 0.89 
BASELINE TRANSTHORACIC ECHOCARDIOGRAPHY 
LV Maximal Wall Thickness  452 9.4  ± 1.8 9.6  ± 1.8 8.9  ± 1.7 <0.001 
Left Atrium Size PLAX view (mm) 376 39 ± 9 42  ± 8 34  ± 7 <0.001 
LV End-Diastolic Diameter (mm) 442 57 ± 10 62 ± 9 48 ± 5 <0.001 
LV Ejection Fraction (%) 520 39 ± 17 30  ± 11 59  ± 6 <0.001 
BASELINE 24-HOUR HOLTER 
AF 272 44 (16%) 37 (17%) 7 (14%) 0.55 
NSVT  272 126 (46%) 121 (55%) 5 (10%) <0.001 
VE Burden/24hr  - Median (IQR) 165 213 [11-1765] 340 [35-2974] 12 [1-256] <0.001 
BASELINE CARDIAC MRI 
Indexed LV End-Diastolic Volume (ml/m2) 153 115 ± 39  123 ± 40 89 ± 18 <0.001 
LV Ejection Fraction (%)  180 40 ± 15  35 ± 13 58 ± 7 <0.001 
 2 
RV Ejection Fraction (%) 142 51 ± 13 49 ± 14 59 ± 7 <0.001 
Indexed LV Mass (g/m2) 76 69 ± 21 72 ± 22 57 ± 15 0.004 
Late Gadolinium Enhancement 178 83 (47%) 78 (53%) 5 (16%) <0.001 
EXTRA-CARDIAC PHENOTYPE 













TABLE 2:  








95% CI Multivariable  
p-value 
Age / 10 1.08 0.92-1.26 0.33    
Proband 1.79 1.02-3.17 0.04 1.01 0.51-1.99 0.98 
Male Sex 2.42 1.38-4.27 0.002 1.89 1.04-3.44 0.04 
TTNtv Type (cf. splice):       
                 Nonsense 1.15 0.40-3.31 0.80    
                 Frameshift 1.45 0.50-4.22 0.50    
TTN A-Band 2.12 1.11-4.05 0.02    
LV Dilatation  2.12 1.09-4.14 0.03    
LVEF (per 10% decrement from LVEF 50%) 1.71 1.40-2.10 <0.001  1.63 1.30-2.04 <0.001 
NSVT*  3.80 1.69-8.52 0.001     
Frequent VE  1.25 0.35-4.46 0.74     














FIGURE 2B:  
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**16 (3%) patients had multiple endpoint events
25 patients 
developed
LVSD over 
follow-up
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FIGURE 5A: 
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FIGURE 5B: 
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FIGURE 5C: 
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FIGURE 5D: 
 
